Equities

Poolbeg Pharma PLC

POLB:LSE

Poolbeg Pharma PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)4.60
  • Today's Change0.20 / 4.55%
  • Shares traded2.55m
  • 1 Year change-10.68%
  • Beta2.0763
Data delayed at least 20 minutes, as of Feb 06 2026 16:42 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Poolbeg Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on the development of medicines to address unmet medical needs. Its clinical programmes target addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions, such as obesity with the development of an oral encapsulated glucagon-like peptide (GLP-1R) agonist. Its pipeline includes POLB 001 Oncology, POLB 001 Influenza, AI Programmes and Oral Encapsulated GLP-1programme. POLB 001 is an orally delivered p38 MAP Kinase inhibitor being developed for the prevention of CRS associated with Bispecific Antibodies and CAR T immunotherapy treatments in cancer. It uses artificial intelligence to identify infectious disease drug targets & treatments. The Oral Encapsulated GLP-1 programme leverages an advanced delivery system that encapsulates active pharmaceutical ingredients using Generally Regarded as Safe (GRAS) components.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-5.71m
  • Incorporated2021
  • Employees10.00
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Futura Medical PLC7.93m-6.29m7.41m12.007.41m12.00
OptiBiotix Health PLC1.15m-191.00k7.90m5.007.90m5.00
IXICO PLC6.53m-1.65m9.50m79.009.50m79.00
Genflow Biosciences PLC0.00-1.80m10.36m5.0010.36m5.00
Solvonis Therapeutics PLC0.00-2.60m17.02m--17.02m--
Fusion Antibodies PLC1.60m-1.47m20.00m24.0020.00m24.00
Sareum Holdings Plc0.00-4.44m23.47m5.0023.47m5.00
Arecor Therapeutics PLC5.06m-8.10m29.26m37.0029.26m37.00
Poolbeg Pharma PLC0.00-5.71m32.07m10.0032.07m10.00
ImmuPharma PLC0.00-3.93m32.07m6.0032.07m6.00
hVIVO PLC51.28m5.28m41.91m301.0041.91m301.00
Skinbiotherapeutics PLC4.64m-696.25k52.43m41.0052.43m41.00
Data as of Feb 06 2026. Currency figures normalised to Poolbeg Pharma PLC's reporting currency: UK Pound GBX

Institutional shareholders

16.55%Per cent of shares held by top holders
HolderShares% Held
IG Markets Ltd.as of 01 Nov 202527.07m3.88%
Schroder Investment Management Ltd.as of 08 Mar 202324.99m3.59%
Hargreaves Lansdown Fund Managers Ltd.as of 01 Nov 202523.28m3.34%
KW Investment Management Ltd.as of 01 Nov 202513.17m1.89%
HSBC Bank Plc (Market-Maker)as of 01 Nov 20259.64m1.38%
Sterling Investments Management Ltd.as of 01 Nov 20255.04m0.72%
Bank Julius B�r & Co. AGas of 01 Nov 20254.62m0.66%
HSBC Global Asset Management (UK) Ltd.as of 01 Nov 20253.60m0.52%
J. M. Finn & Co. Ltd.as of 01 Nov 20252.49m0.36%
Schroder Investment Management (Switzerland) AGas of 01 Nov 20251.47m0.21%
More ▼
Data from 31 Jan 2025 - 02 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.